Patents Examined by Lisa V. Cook
  • Patent number: 11408886
    Abstract: Provided are a method of screening for novel therapeutic targets to develop therapeutic agents for colon cancer, and prognostic biomarkers for colon cancer treatment which are screened using the same.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: August 9, 2022
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Min-Jung Kang, Byung Hwa Jung, Young Sook Yoo, Thanh Binh Nguyen
  • Patent number: 11406710
    Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 9, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Chad May, Robert B. Dubridge, Maia Vinogradova, Anand Panchal
  • Patent number: 11408888
    Abstract: Provided are methods, assays, and kits for detecting hepatocellular carcinoma, as well as methods for stratifying subjects among higher and lower risk categories for having hepatocellular carcinoma, and methods of treating and managing treatment of subjects that are suspected or at risk of having hepatocellular carcinoma. Although previous work has attempted to address the need for a highly sensitive, early predictor of hepatocellular carcinoma by assessment of one or more biological factors, none have approached the degree of sensitivity that is required for clinically relevant determination of whether a subject, especially a non-symptomatic subject, has that condition. The present inventors have discovered that certain combinations of factors fulfill this need by conferring a high level of accuracy that was not previously attainable.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: August 9, 2022
    Assignee: Drexel University
    Inventors: Timothy M. Block, Mengjun Wang, Anand Mehta, Mary Ann Comunale
  • Patent number: 11408896
    Abstract: An embodiment relates to a method, comprising: obtaining a biological sample, performing a protein complex immunoprecipitation (Co-IP) on the sample, performing a reverse phase protein array (RPPA) on the sample after performing the protein complex immunoprecipitation, and identifying one or more protein complexes. A further embodiment relates to a method of treatment, comprising: obtaining a tissue sample from a patient, performing Co-IP then RPPA on the sample, identifying a protein complex, determining whether the protein complex comprises known protein drug targets, and treating the patient with a drug that interacts with the known protein drug targets.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: August 9, 2022
    Assignee: George Mason University
    Inventors: Mariaelena Pierobon, Emanuel Petricoin, Elisa Baldelli
  • Patent number: 11391744
    Abstract: The present invention relates to methods for detecting the presence of Mcm5 in a subject, the method comprising preparing a sample from said subject by exposing the sample to a lysis buffer and performing an assay to determine the concentration of Mcm5 by exposing the sample to a first monoclonal antibody and/or a second monoclonal antibody and measuring the amount of Mcm5 that binds to the first monoclonal antibody and/or the second monoclonal antibody. The invention further relates to kits that can be used in the methods.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: July 19, 2022
    Assignee: ARQUER DIAGNOSTIC LIMITED
    Inventors: David Nicholas Miller-Jones, Cheryl Nyberg, Ronald Alfred Laskey, Kai Stoeber
  • Patent number: 11376326
    Abstract: The present invention provides a method for determining the efficacy of a GPC3-targeting therapeutic agent for a liver cancer patient and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective. The present invention provides, for example, a method for determining that a GPC3-targeting therapeutic agent is effective when the expression level of GPC3 per tumor cell is a predetermined value, and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: July 5, 2022
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Toshihiko Ohtomo, Takayoshi Tanaka, Yasuo Sugitani
  • Patent number: 11360093
    Abstract: The present invention relates to a colorectal cancer diagnostic composition and method for detecting a diagnostic marker, more specifically to a colorectal cancer diagnostic composition comprising one or more mRNAs selected from the group consisting of lysyl-tRNA synthetase (KRS) and aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1) of a preparation for measuring protein expression levels thereof, and a method for detecting a marker form a sample obtained from a test subject in order to provide information necessary for diagnosing colorectal cancer. The colorectal cancer diagnostic marker comprising KRS and AIMP1, according to the present invention, has raised expression levels of same in the serum of a colorectal cancer patient in comparison to a normal control group. Therefore, whether colorectal cancer is present can be accurately and rapidly determined by measuring the expression levels of one or more markers selected from the group consisting of KRS and AIMP1.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: June 14, 2022
    Assignee: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Sunghoon Kim, Min Chul Park, Peter Charles Goughnour
  • Patent number: 11360098
    Abstract: Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (A?42) to amyloid beta 40 (A?40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: June 14, 2022
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Diana Tran, Darren Weber, Nigel Clarke
  • Patent number: 11340234
    Abstract: Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-region binding fragment thereof so that a complex between the anti-drug antibody against the effector function suppressed human or humanized drug antibody present in the sample and the human Fcgamma receptor I or the Fc-region binding fragment thereof forms, whereby the full length human Fcgamma receptor I or the Fc-region binding fragment thereof is conjugated to a detectable label, and the determination of the formed complex by the detectable label.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: May 24, 2022
    Inventors: Pablo Umana, Uwe Wessels, Kay-Gunnar Stubenrauch
  • Patent number: 11339219
    Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: May 24, 2022
    Assignee: The Johns Hopkins University
    Inventors: Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
  • Patent number: 11333659
    Abstract: Provided herein are methods for simultaneously determining the functional status of multiple signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a targeted therapeutic agent that affects the signaling pathway with the highest level of aberrant activity in the subject's cells. Also provided are methods for determining whether a signaling pathway is ultrasensitive in a diseased cell sample from a subject, also allowing for selection of an effective targeted therapeutic agent for therapeutic use in the subject. Methods of administering a selected targeted therapeutic agent to the subject are also provided.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: May 17, 2022
    Assignee: Celcuity Inc.
    Inventors: Lance Gavin Laing, Brian Francis Sullivan
  • Patent number: 11333665
    Abstract: The present disclosure relates to a method of isolating extracellular vesicles directly from human tissues. The invention further relates to a method of identifying disease and tissue specific membrane proteins on extracellular vesicles by membrane isolation and proteomic analysis. The invention further relates to methods of diagnosing diseases by capturing extracellular vesicles by the use of disease specific membrane proteins from body fluids, and detecting or analyzing molecular signatures (proteome, DNA, and RNA) on captured extracellular vesicles. Moreover, the present invention relates to kits, apparatus and software required for implementing aforementioned methods.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: May 17, 2022
    Assignee: Exocure Biosciences, Inc.
    Inventors: Jan Lotvall, Su Chul Jang, Rossella Crescitelli
  • Patent number: 11325974
    Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: May 10, 2022
    Assignee: The Johns Hopkins University
    Inventors: Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
  • Patent number: 11325975
    Abstract: Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: May 10, 2022
    Assignee: The Johns Hopkins University
    Inventors: Luis Diaz, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Dung Le, Drew M. Pardoll, Suzanne L. Topalian
  • Patent number: 11320423
    Abstract: Disclosed is an immunoassay method for detecting an analyte such as an antigen or an antibody in an isolated sample suspected to contain the analyte by incubating the sample with a plurality of binding partners, one of which carries a detectable label, wherein a label-specific binding partner is added that does not carry a label but binds to the detectable label. The method is applicable for a large variety of analytes and has proven particularly useful for analyte antibodies of the IgG and IgM class present in samples due to infections by pathogens. Also disclosed is a reagent kit useful for the method comprising at least two analyte-specific binding partners one of which carries a detectable label and a label-specific binding partner that binds to said detectable label but itself does not carry a detectable label.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 3, 2022
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Barbara Upmeier, Toralf Zarnt, Dieter Roessler, Johannes Polz
  • Patent number: 11312940
    Abstract: Provided are methods for isolating subpopulations of stem cells. In some embodiments, the presently disclosed methods include selecting subsets of cells that are positive for CD34 or Sca-1, are further positive for one or more of FSHR, LHCGR, PRLR, AR, ESR?, ESR?, and PGR; and are negative for each of CD45R/B220, Gr-1, TCR??, TCR??, CD11b, and Ter-119. In some embodiments, the subpopulations are further fractioning into CD45? and CD45+ fractions. Also provided are populations of stem cells isolated by the presently disclosed methods, compositions that include the presently disclosed subpopulations in pharmaceutically acceptable carriers, methods for expanding stem cells, methods for stimulating proliferation of MSCs, methods for treating subjects suffering from exposure to radiation, and methods for producing gametes in vitro.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: April 26, 2022
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Mariusz Z. Ratajczak, Janina Ratajczak, Magdalena Kucia
  • Patent number: 11287416
    Abstract: The invention relates to cancer, and in particular to novel pharmaceutical compositions, therapies and methods for treating, preventing or ameliorating cancer, and especially metastatic disease. The invention also relates to diagnostic and prognostic methods for cancer and metastatic disease, and biomarkers for these conditions.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: March 29, 2022
    Assignee: NEURO-BIO LTD
    Inventors: Susan Adele Greenfield, Henry Tu, Paul Morrill, Sara Garcia-Rates, Chris Pepper, Chris Fegan
  • Patent number: 11268963
    Abstract: Described are optical methods and reagents for sequencing polypeptides. A probe that exhibits different spectral properties when conjugated to different N-terminal amino acids is conjugated to the N-terminal amino acid of a polypeptide. Sequentially detecting one or more spectral properties of the probe conjugated to the N-terminal amino acid and cleaving the N-terminal amino acid produces sequence information of the polypeptide. The use of super-resolution microscopy allows for the massively parallel sequencing of individual polypeptide molecules in situ such as within a cell. Also described are probes comprising hydroxymethyl rhodamine green, an isothiocyanate group and a protecting group.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: March 8, 2022
    Inventor: Andrew Emili
  • Patent number: 11241395
    Abstract: In vitro methods such as in vitro diagnosis, prognosis and risk stratification of a patient having a primary disease, whereby the level of Procalcitonin (PCT) or fragment thereof in a sample of a bodily fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition. Assays for performing such methods and samples containing complex resulting from such methods.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: February 8, 2022
    Assignee: B.R.A.H.M.S. GmbH
    Inventors: Joachim Struck, Andreas Bergmann
  • Patent number: 11243208
    Abstract: Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: February 8, 2022
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Benjamin Katchman, Karen Anderson, Garrick Wallstrom, Joshua LaBaer, Daniel Cramer